Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2025CancersOpen Access

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTasmia TahsinDMDarius K. McPhailJCJesse D. Champion

Discussion

Loading...

Member takes

Overview

Observational analysis shows NRF2 and FSP1 impact ferroptosis resistance in TSC2-deficient cancers, suggesting targeted therapy benefits.

Key Points

  • TSC2-deficient cells resist ferroptosis due to antioxidant responses that counter lipid peroxidation, affecting treatment outcomes.
  • Pharmacological inhibition of NRF2 resensitized TSC2-deficient cells to ferroptosis, confirming it as a protective factor.
  • FSP1 knockdown enhanced ferroptosis sensitivity significantly in ovarian and breast cancer cells, indicating distinct mechanisms.
  • Targeting NRF2 and FSP1 suggests a need for tailored strategies in ferroptosis resistance, which varies across cancer types.

Cite This Study

Tahsin et al. (2025) studied this question.

synapsesocial.com/papers/68af6d967567bf4f94feb5bchttps://doi.org/10.3390/cancers17162714
View Full Paper
Ask AI
Bookmark
Share